Investor Presentation Q1-Q3 2020

40 Investor presentation First nine months of 2020 Novo Nordisk has a strong leadership position within the growing diabetes market Global diabetes market by treatment class¹ Novo Nordisk remains global diabetes value market leader Novo Nordisk market share and share of growth Novo NordiskⓇ DKK billion 350 35% 60% Market CAGR²: 8.5% 29% 300 30% 50% 250 25% CAGR: 6.7% 40% 36% 200 CAGR: 192.7% 20% 30% 150 CAGR: 29.5% 15% 29% 20% 100 CAGR: 0.4% 10% 10% 50 5% 0 0% 0% Aug Aug Aug 14FY 15FY 16FY 17FY 18FY 19FY 2010 2020 2017 Aug 2020 Novo Nordisk -Takeda NN market share NN share of growth Insulin GLP-1 SGLT2 DPP-4 Sanofi Merck AstraZeneca Eli Lilly BI Novartis J&J 1 Data is based on company reported sales from Sanofi, Eli Lilly, AstraZeneca, GSK, Novartis, Johnson & Johnson, and Merck. Data does not include generic metformin, sulphonylureas or thiazolidinedione 2 CAGR for 5-year period OAD: Oral anti-diabetic; NN: Novo Nordisk; Source: IQVIA MAT, Aug 2020 value figures Note: IQVIA data can be inflated due to use of list prices in the US; BI: Boehringer Ingelheim

View entire presentation